{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:39:55Z","timestamp":1785886795343,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Project of Shanghai Science and Technology Commission","award":["134119b1500"],"award-info":[{"award-number":["134119b1500"]}]},{"name":"Natural Science Project of Shanghai University of Traditional Chinese Medicine","award":["18LK077"],"award-info":[{"award-number":["18LK077"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Secondary osteoporosis may occur in patients with rheumatoid arthritis (RA), causing irreversible joint damage and disability. Bisphosphonates, the recently developed bone resorption inhibitors, have demonstrated significant therapeutic effects on senile and postmenopausal osteoporosis. This study evaluated the efficacy and safety of zoledronic acid (ZOL), with or without methotrexate (MTX), for the prevention and treatment of bone destruction in RA patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We recruited 66 RA patients with symptoms of secondary osteoporosis. They were randomized into three treatment groups\u2014combined treatment with MTX and ZOL, ZOL monotherapy, or MTX monotherapy\u2014in two consecutive 6-month periods. The participants were followed for 12\u2009months. At the end of each treatment period, improvement in disease activity, bone destruction, and fracture risk were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Combined treatment with ZOL and MTX had significantly better clinical efficacy compared with either ZOL or MTX monotherapy (<jats:italic>P<\/jats:italic> &lt; 0.05). The combination significantly improved the lumbar spine and hip BMD and reduced FRAX scores, suggesting that ZOL combined with MTX reduces bone loss and risk of hip fracture in RA patients with secondary osteoporosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ZOL has a synergistic effect when combined with MTX, inhibiting RA disease activity, reducing fracture risk, and improving quality of life in RA patients with secondary osteoporosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Chinese Clinical Trial Registry, ChiCTR1800019290. Registered 3 November 2018\u2013Retrospective registered, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj\">http:\/\/www.chictr.org.cn\/showproj.aspx?proj<\/jats:ext-link> = 31758<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13018-019-1492-3","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T11:04:07Z","timestamp":1575975847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients"],"prefix":"10.1186","volume":"14","author":[{"given":"Jun","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianbo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubiao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"issue":"10","key":"1492_CR1","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1007\/s00198-017-4170-5","volume":"28","author":"L Heinlen","year":"2017","unstructured":"Heinlen L, Humphrey MB. Skeletal complications of rheumatoid arthritis. Osteoporosis Int. 2017;28(10):2801\u201312.","journal-title":"Osteoporosis Int"},{"issue":"1","key":"1492_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1\u201326.","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"1492_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/art.23177","volume":"58","author":"CG Helmick","year":"2008","unstructured":"Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15\u201325.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1492_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13075-017-1457-z","volume":"19","author":"S Jin","year":"2017","unstructured":"Jin S, Li M, Fang Y, Li Q, Liu J, Duan X, et al. Chinese Registry of rheumatoid arthritis (CREDIT): II. Prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis. Arthritis Res therapy. 2017;19(1):251.","journal-title":"Arthritis Res therapy"},{"issue":"3","key":"1492_CR5","first-page":"300","volume":"13","author":"X Zeng","year":"2013","unstructured":"Zeng X, Zhu S, Tan A, Xie X. Disease burden and quality of life of rheumatoid arthritis in China: a systematic review. Chin J Evid Based Med. 2013;13(3):300\u20137.","journal-title":"Chin J Evid Based Med"},{"issue":"3","key":"1492_CR6","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y","volume":"43","author":"G Haugeberg","year":"2000","unstructured":"Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000;43(3):522\u201330.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1492_CR7","first-page":"2582","volume":"27","author":"L Sinigaglia","year":"2000","unstructured":"Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol. 2000;27(11):2582\u20139.","journal-title":"J Rheumatol"},{"issue":"2","key":"1492_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1055\/s-0038-1660790","volume":"6","author":"I Akkawi","year":"2018","unstructured":"Akkawi I, Zmerly H. Osteoporosis: current concepts. Joints. 2018;6(2):122\u20137.","journal-title":"Joints"},{"issue":"7","key":"1492_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/ard.62.7.611","volume":"62","author":"E Lindqvist","year":"2003","unstructured":"Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10\u2009years in a cohort with early rheumatoid arthritis. Ann Rheum Dis. 2003;62(7):611\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1492_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","volume":"49","author":"MJ Rogers","year":"2011","unstructured":"Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011;49(1):34\u201341.","journal-title":"Bone"},{"issue":"5","key":"1492_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/rheumatology\/keg209","volume":"42","author":"SS Shin","year":"2003","unstructured":"Shin SS, Jin M, Jung HJ, Kim B, Jeon H, Choi JJ, et al. Suppressive effects of PG201, an ethanol extract from herbs, on collagen-induced arthritis in mice. Rheumatology (Oxford). 2003;42(5):665\u201372.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1492_CR12","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/art.21824","volume":"54","author":"SJ Jarrett","year":"2006","unstructured":"Jarrett SJ, Conaghan PG, Sloan VS, Papanastasiou P, Ortmann CE, O'Connor PJ, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum. 2006;54(5):1410\u20134.","journal-title":"Arthritis Rheum"},{"key":"1492_CR13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12891-016-1167-8","volume":"17","author":"R Meinen","year":"2016","unstructured":"Meinen R, Galli-Lysak I, Villiger PM, Aeberli D. Influence of bisphosphonate therapy on bone geometry, volumetric bone density and bone strength of femoral shaft in postmenopausal women with rheumatoid arthritis. BMC Musculoskelet Disord. 2016;17:324.","journal-title":"BMC Musculoskelet Disord"},{"issue":"S5","key":"1492_CR14","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1002\/art.11407","volume":"49","author":"J Fransen","year":"2003","unstructured":"Fransen J, Stucki G, van Riel PLCM. Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Care Res (Hoboken). 2003;49(S5):S214\u2013S24.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"10","key":"1492_CR15","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F. Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014;25(10):2359-81.","journal-title":"Osteoporosis International"},{"issue":"6","key":"1492_CR16","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1097\/00000542-200112000-00013","volume":"95","author":"CA Bodian","year":"2001","unstructured":"Bodian CA, Freedman G, Hossain S, Eisenkraft JB, Beilin Y. The visual analog scale for pain: clinical significance in postoperative patients. Anesthesiology. 2001;95(6):1356\u201361.","journal-title":"Anesthesiology."},{"key":"1492_CR17","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","volume":"158","author":"W Wang","year":"2018","unstructured":"Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem. 2018;158:502\u201316.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"1492_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/cvr\/cvt230","volume":"100","author":"SH Tsai","year":"2013","unstructured":"Tsai SH, Huang PH, Peng YJ, Chang WC, Tsai HY, Leu HB, et al. Zoledronate attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of Rho\/ROCK-dependent JNK and NF-kappaB pathway. Cardiovasc Res. 2013;100(3):501\u201310.","journal-title":"Cardiovasc Res"},{"key":"1492_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.coph.2018.03.006","volume":"40","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, Ohira T. Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. Curr Opin Pharmacol. 2018;40:110\u20139.","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"1492_CR20","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/1529-0131(200004)43:4<821::AID-ANR12>3.0.CO;2-T","volume":"43","author":"E Romas","year":"2000","unstructured":"Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF, et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 2000;43(4):821\u20136.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1492_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1006\/bbrc.1999.1623","volume":"265","author":"NJ Horwood","year":"1999","unstructured":"Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun. 1999;265(1):144\u201350.","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"1492_CR22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821\u201331.","journal-title":"N Engl J Med"},{"issue":"10","key":"1492_CR23","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1359\/JBMR.050601","volume":"20","author":"M Stolina","year":"2005","unstructured":"Stolina M, Adamu S, Ominsky M, Dwyer D, Asuncion F, Geng Z, et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res. 2005;20(10):1756\u201365.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1492_CR24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S0002-9440(10)64417-3","volume":"161","author":"E Romas","year":"2002","unstructured":"Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol. 2002;161(4):1419\u201327.","journal-title":"Am J Pathol"},{"issue":"5","key":"1492_CR25","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/S0002-9440(10)63016-7","volume":"159","author":"AR Pettit","year":"2001","unstructured":"Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, et al. TRANCE\/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 2001;159(5):1689\u201399.","journal-title":"Am J Pathol"},{"issue":"1","key":"1492_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00011-005-0005-5","volume":"55","author":"T Neumann","year":"2006","unstructured":"Neumann T, Oelzner P, Petrow PK, Thoss K, Hein G, Stein G, et al. Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis. Inflammation Res. 2006;55(1):32\u20139.","journal-title":"Inflammation Res"},{"issue":"1","key":"1492_CR27","first-page":"23","volume":"84","author":"M Muratore","year":"2013","unstructured":"Muratore M, Quarta E, Quarta L. Intramuscular neridronate in patients with rheumatoid arthritis using corticosteroids: evaluation of treatment adherence in a randomized, open-label comparison with other bisphosphonates. Acta Biomed. 2013;84(1):23\u20139.","journal-title":"Acta Biomed"},{"issue":"1","key":"1492_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/art.39429","volume":"68","author":"JH Koh","year":"2016","unstructured":"Koh JH, Myong JP, Jung SM, Lee J, Kwok SK, Park SH, et al. Atypical femoral fracture in rheumatoid arthritis patients treated with bisphosphonates: a nested case-control study. Arthritis Rheumatol. 2016;68(1):77\u201382.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1492_CR29","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00198-011-1800-1","volume":"23","author":"C Roux","year":"2012","unstructured":"Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, et al. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int. 2012 Mar;23(3):1083\u201390.","journal-title":"Osteoporos Int"},{"issue":"9671","key":"1492_CR30","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253\u201363.","journal-title":"Lancet"},{"issue":"8","key":"1492_CR31","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/jbmr.2825","volume":"31","author":"DW Dempster","year":"2016","unstructured":"Dempster DW, Roschger P, Misof BM, Zhou H, Paschalis EP, Alam J, et al. Differential effects of teriparatide and zoledronic acid on bone mineralization density distribution at 6 and 24\u2009months in the SHOTZ study. J Bone Miner Res. 2016;31(8):1527\u201335.","journal-title":"J Bone Miner Res."}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-019-1492-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13018-019-1492-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-019-1492-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T01:46:08Z","timestamp":1607478368000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-019-1492-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1492"],"URL":"https:\/\/doi.org\/10.1186\/s13018-019-1492-3","relation":{},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"29 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was given by the Ethics Committee of the Tenth Hospital Affiliated to Nanjing Medical University, Shanghai, China. All patients gave their written informed consent. Clinical registration number: ChiCTR1800019290.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"421"}}